Biogen reports Q2 2026: $2.74B revenue, GAAP EPS $0.66, Non‑GAAP EPS $3.60

{
  "signal_id": "5f0bdb83-387f-4fb5-28b7-58420aa7908f",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-07-29T10:13:01+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/tradingview:5d70eb587d1d2:0-biogen-reports-q2-2026-2-74b-revenue-gaap-eps-0-66-non-gaap-eps-3-60/",
    "title": "Biogen reports Q2 2026: $2.74B revenue, GAAP EPS $0.66, Non‑GAAP EPS $3.60 - TradingView",
    "excerpt": "Biogen reported second-quarter 2026 results with total revenue of $2.74 billion, up 3% year‑over‑year, and GAAP diluted EPS of $0.66 and non‑GAAP diluted EPS of $3.60. The company highlighted Growth Portfolio revenue of $1.06 billion (24% year‑over‑year growth) and continued commercial momentum from recently acquired products. Management reiterated a multi‑year late‑stage data flow and updated full‑year 2026 non‑GAAP EPS guidance to $12.00–$13.00 reported (underlying $15.85–$16.85 before acquisition and IPR&D impacts). Financial Highlights Business Highlights Original SEC Filing: BIOGEN INC. [ BIIB ] - 8-K - Jul. 29, 2026",
    "summary": "Biogen reported second-quarter 2026 GAAP diluted EPS of $0.66 and non-GAAP diluted EPS of $3.60.",
    "planning": false,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.95,
    "published_at": "2026-07-29T10:13:01Z",
    "article_sentence": "Biogen reported second-quarter 2026 results with total revenue of $2.74 billion, up 3% year‑over‑year, and GAAP diluted EPS of $0.66 and non‑GAAP diluted EPS of $3.60."
  }
}

curl https://signals.autobound.ai/v1/signals/5f0bdb83-387f-4fb5-28b7-58420aa7908f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'